Background & objective: CAF regimen [Cytoxan+ Adriamycin+5-fluorouracil (5-FU)] and TP regimen (paclitaxel+cisplatin) were effective to advanced breast cancer (ABC). But TP regimen was expensive and the administration was complicated. So the authors evaluated the clinical results of CAF and TP regimens.
Methods: A total of 117 ABC patients proved pathologically were divided into CAF and TP groups. Patients in both groups were well matched with baseline disease characteristics (P >0.05). CAF group (66 cases):received Cytoxan 600 mg/m(2), i.v. drip d(1), Adriamycin 60 mg/m(2) i.v. drip d(1) and 5-FU 600 mg/m(2), i.v. drip d(1,8); TP group (51 cases): received paclitaxel 135 mg/m(2) by i.v. drip for 3 hours and cisplatin 60 mg/m(2), i.v. drip d(2-3) The treatments were repeated every 3 weeks. All patients received two cycles of the treatment at least.
Results: In CAF group, the response rates (RR) of the initial treatment cases, the retreatment cases, and the whole cases were 54.8% (17/31), 31.4% (11/35), and 42.4% (28/66), respectively. The median time to progression (TTP) was 7.8 months (95%CI:5.3-10.8 months) and the median survival was 17.8 months (95%CI:13.3-22.5%). Whereas in TP group, the RR of the initial treatment cases, the retreatment cases, and the whole cases were 62.5%(15/24), 59.3%(16/27), and 60.8%(31/51), respectively. The median TTP and the median survival were 8.6 months (95%CI:6.5-12 months) and 19 months (95%CI:15-25.5 months), respectively. There were significant differences between two groups in the RR of retreatment cases and the whole cases (P< 0.05, Chi-square test). However, there was no significant difference in the RR of the initial treatment cases, the median TTP and median survival (for RR, P >0.05, Chi-square test; for median TTP and median survival, P >0.05, Log-rank test). Diarrhea was more serious in CAF group than in TP group; however, myodynia, peripheral neuropathy,and skin exanthem were more serious in TP group than in CAF group(P< 0.05,Wilcoxon rank sum test). There was no significant difference in the other side effects between the two groups. All side effects were tolerable.
Conclusion: CAF regimen was still a firstly selected regimen for the patients with ABC.